Meridian illumigene® Streptococcus Tests Now 'Moderate Complexity'
Group B Streptococcus (GBS) continues to be a major perinatal pathogen, for both mothers and their infants, and is associated with significant morbidity and mortality. Group B Streptococcus fully complies with the CDC guidelines for the detection of GBS and clinical studies have shown that broth enrichment, followed by testing with illumigene Group B Streptococcus, increased detection of true positives by 29% over traditional culture, thus allowing for appropriate treatment of mother at time of delivery, ensuring the best outcome for baby.
Jack Kraeutler, Chief Executive Officer, stated, Due to its simplicity and superior accuracy, our illumigene technology platform enables most clinical labs to perform sophisticated molecular diagnostics without the high costs of capital equipment and ongoing service charges. The Moderate Complexity classification of the illumigene Group A Streptococcus test and the illumigene Group B Streptococcus test, along with illumigene C. difficile, enables more labs to adopt molecular testing thereby helping to provide better patient outcomes.
Tags: Clostridium difficile, Streptococcus, Pathogen, FDA, Group A Streptococcus
Date Published: March 26, 2013
Source article link: Meridian » company contact details
Group A Strep Detection in 18 Minutes With FDA and CLIA Waiver
Ultrasensitive C. diff Toxins A/B Assay Based on Single Molecule Counting Technology
TECHLAB Products Meet Updated IDSA/SHEA Guidelines for C. difficile
New Website for C. diff Professionals - www.knowyourpoo.com
GC and CFU Correlation Of 9 Mycoplasma spp Examined With Sartorius' Microsart® Range